Document is current
Any future updates will be listed below
-
Authors
Choi, Bryan D.
Yu, Xiaoling
Castano, Ana P.
Darr, Henia
Henderson, Daniel B.
Bouffard, Amanda A.
Larson, Rebecca C.
Scarfò, Irene
Bailey, Stefanie R.
Gerhard, Genevieve M.
Frigault, Matthew J.
Leick, Mark B.
Schmidts, Andrea
Sagert, Jason G.
Curry, William T.
Carter, Bob S.
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
-
Funding
Funding for this research was provided by:
CRISPR Therapeutics (NA)
National Institutes of Health (R25NS065743)
Neurosurgery Research and Education Foundation (NA)
B*Cured (NA)
Society for Immunotherapy of Cancer (NA)
Damon Runyon Cancer Research Foundation (NA)
Stand Up To Cancer (NA)
The Jenny Fund (NA)
- License Information
-
More Information
Article History
Received: 29 May 2019
Accepted: 6 November 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: All experiments in this study were performed under protocols reviewed by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
: Not applicable.
: B.D.C. and M.V.M are inventors on patents related to the use of engineered cell therapies and bispecific T-cell engagers for GBM and other cancers. B.D.C. received commercial research grants from ACEA Biosciences. M.V.M. received commercial research grants from Kite Pharma, TCR2, Agentus, and CRISPR Therapeutics, and is a consultant or advisory board member for Adaptimmune, Agentus, Cellectis, CRISPR Therapeutics, Kite Pharma, Novartis, TCR2, and Windmil (unrelated to this work). H.D., D.B.H., and J.G.S. are employees at CRISPR Therapeutics who possess stock or options in the company.
